Cardiovascular effects of intravenous (i. v.) treatment with the essential oil of Mentha x villosa (EOMV) were investigated in pentobarbitone-anaesthetised rats. Additionally this study examines whether the major constituent of EOMV, piperitenone oxide (PO), is the active principle mediating EOMV-induced changes in mean aortic pressure (MAP) and heart rate (HR) and whether the autonomic nervous system is involved in the mediation of these cardiovascular effects. Two samples of EOMV have been tested: one contained 62.32% of PO (sample 1) and the other contained a higher percent (95.87%) of PO (sample 2). Intravenous injections of bolus doses (1 to 20 mg/kg) of both samples of EOMV elicited immediate and dose-dependent decreases in MAP and HR. These cardiovascular responses were also observed following i. v. injections of PO (1 to 20 mg/kg). However, maximal percent decreases in MAP and HR elicited by sample 2 of EOMV were significantly greater than those evoked by sample 1 of EOMV, while they were of the same order of magnitude as those elicited by PO. Pretreatment of rats with either bilateral vagotomy or i. v. methylatropine (1 mg/kg) did not modify significantly the hypotensive and bradycardic responses to EOMV. In contrast, pretreatment with i. v. hexamethonium (30 mg/kg) partially, but significantly, reduced the bradycardic effects of EOMV without affecting hypotension. The present study shows for the first time that i. v. treatment with EOMV in pentobarbitone-anaesthetised rats induces hypotensive and bradycardic effects, which appear mostly attributed to the actions of the major constituent of EOMV, PO. These cardiovascular effects appear to be independent since EOMV-induced bradycardia appears dependent upon the presence of an intact and functional sympathetic nerve drive to the heart, while EOMV-induced hypotension appears independent of the presence of an operational sympathetic nervous system. This suggests that hypotensive activity of EOMV may result from its vasodilatory effects directly upon vascular smooth muscle.
Introduction:Posture is determined by the performance of the visual, somatosensory and vestibular systems. Children with hearing loss can present problems in their posture or postural control, enabling postural deviations and alterations to appear in their vertebral column, possibly provoked by a hypoactivity of the vestibular system as a result of deafness.
Objective:To evaluate the posture of the vertebral column in children and teenagers with hearing loss at school age, taking into consideration the sample gender and age.
Method:A descriptive and prospective study was performed at both Duque de Caxias School and Rotary Rehabilitation and Special Education Center in Caruaru -Pernambuco. 44 students aged between 7-17 years old, out of whom 22 were female and 22 were male, with hearing loss were evaluated. The study was developed by way of a postural evaluation, using a symmetrograph, marking specific anatomical points with stickers placed over polystyrene balls and fixed with double-sided adhesive tape.
Results:The results showed that all of the individuals evaluated in this study presented some kind of postural alteration in their vertebral column. Scoliosis was the most observed alteration among the students (84.1%), followed by thoracic hyperkyphosis (68.2%).
Conclusion:It has been concluded that children and teenagers with hearing loss are exposed to postural alteration in their vertebral column. Such a condition can be associated with a number of factors comprising unfavorable ergonomics of the school environment, bad postural habits and impairment of the vestibular system by virtue of the hearing loss.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.